Infections After Adoption of Antibiogram-directed Prophylaxis and Intracorporeal Urinary Diversion for Robot-assisted Radical Cystectomy.

Antibiogram Bladder cancer Infection Intracorporeal urinary diversion Radical cystectomy Robotic surgery

Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
12 Oct 2023
Historique:
received: 30 07 2023
revised: 01 09 2023
accepted: 19 09 2023
medline: 15 10 2023
pubmed: 15 10 2023
entrez: 14 10 2023
Statut: aheadofprint

Résumé

Enhanced recovery after surgery (ERAS) has significantly decreased the morbidity associated with radical cystectomy. However, infectious complications including sepsis, urinary tract (UTIs), wound (WIs), and intra-abdominal (AIs) infections remain common. To assess whether intracorporeal urinary diversion (ICUD) and antibiogram-directed antimicrobial prophylaxis would decrease infections after robotic-assisted radical cystectomy (RARC). A retrospective analysis was performed of a prospectively maintained database of patients undergoing RARC between 2014 and 2022 at a tertiary care institution, identifying two groups based on adherence to a prospectively implemented modified ERAS protocol for RARC: modified-ERAS-ICUD and antibiogram-directed ampicillin-sulbactam, gentamicin, and fluconazole prophylaxis were utilized (from January 2019 to present time), and unmodified-ERAS-extracorporeal urinary diversion (UD) and guideline-recommended cephalosporin-based prophylaxis regimen were utilized (from November 2014 to June 2018). Patients receiving other prophylaxis regimens were excluded. ICUD and antibiogram-directed infectious prophylaxis. The primary outcome was UTIs within 30 and 90 d postoperatively. The secondary outcomes were WIs, AIs, and sepsis within 30 and 90 d postoperatively, and Clostridioides difficile infection (CDI) within 90 d postoperatively. A total of 396 patients were studied (modified-ERAS: 258 [65.2%], unmodified-ERAS: 138 [34.8%]). UD via a neobladder was more common in the modified-ERAS cohort; all other intercohort demographic differences were not statistically different. Comparing cohorts, modified-ERAS had significantly reduced rates of 30-d (7.8% vs 15.9%, p = 0.027) and 90-d UTIs (11.2% vs 25.4%, p = 0.001), and 30-d WIs (1.2% vs. 8.7%, p < 0.001); neither group had a WI after 30 d. Rates of AIs, sepsis, and CDI did not differ between groups. On multivariate regression, the modified-ERAS protocol correlated with a reduced risk of UTIs and WIs (all p < 0.01). The primary limitation is the retrospective study design. Utilization of ICUD and antibiogram-based prophylaxis correlates with significantly decreased UTIs and WIs after RARC. In this study of infections after robotic radical cystectomy for bladder cancer, we found that intracorporeal (performed entirely inside the body) urinary diversion and an institution-specific antibiogram-directed antibiotic prophylaxis regimen led to fewer urinary tract infections and wound infections at our institution.

Sections du résumé

BACKGROUND BACKGROUND
Enhanced recovery after surgery (ERAS) has significantly decreased the morbidity associated with radical cystectomy. However, infectious complications including sepsis, urinary tract (UTIs), wound (WIs), and intra-abdominal (AIs) infections remain common.
OBJECTIVE OBJECTIVE
To assess whether intracorporeal urinary diversion (ICUD) and antibiogram-directed antimicrobial prophylaxis would decrease infections after robotic-assisted radical cystectomy (RARC).
DESIGN, SETTING, AND PARTICIPANTS METHODS
A retrospective analysis was performed of a prospectively maintained database of patients undergoing RARC between 2014 and 2022 at a tertiary care institution, identifying two groups based on adherence to a prospectively implemented modified ERAS protocol for RARC: modified-ERAS-ICUD and antibiogram-directed ampicillin-sulbactam, gentamicin, and fluconazole prophylaxis were utilized (from January 2019 to present time), and unmodified-ERAS-extracorporeal urinary diversion (UD) and guideline-recommended cephalosporin-based prophylaxis regimen were utilized (from November 2014 to June 2018). Patients receiving other prophylaxis regimens were excluded.
INTERVENTION METHODS
ICUD and antibiogram-directed infectious prophylaxis.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS METHODS
The primary outcome was UTIs within 30 and 90 d postoperatively. The secondary outcomes were WIs, AIs, and sepsis within 30 and 90 d postoperatively, and Clostridioides difficile infection (CDI) within 90 d postoperatively.
RESULTS AND LIMITATIONS CONCLUSIONS
A total of 396 patients were studied (modified-ERAS: 258 [65.2%], unmodified-ERAS: 138 [34.8%]). UD via a neobladder was more common in the modified-ERAS cohort; all other intercohort demographic differences were not statistically different. Comparing cohorts, modified-ERAS had significantly reduced rates of 30-d (7.8% vs 15.9%, p = 0.027) and 90-d UTIs (11.2% vs 25.4%, p = 0.001), and 30-d WIs (1.2% vs. 8.7%, p < 0.001); neither group had a WI after 30 d. Rates of AIs, sepsis, and CDI did not differ between groups. On multivariate regression, the modified-ERAS protocol correlated with a reduced risk of UTIs and WIs (all p < 0.01). The primary limitation is the retrospective study design.
CONCLUSIONS CONCLUSIONS
Utilization of ICUD and antibiogram-based prophylaxis correlates with significantly decreased UTIs and WIs after RARC.
PATIENT SUMMARY RESULTS
In this study of infections after robotic radical cystectomy for bladder cancer, we found that intracorporeal (performed entirely inside the body) urinary diversion and an institution-specific antibiogram-directed antibiotic prophylaxis regimen led to fewer urinary tract infections and wound infections at our institution.

Identifiants

pubmed: 37838593
pii: S2405-4569(23)00212-2
doi: 10.1016/j.euf.2023.09.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Jordan M Rich (JM)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Evan B Garden (EB)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Juan Sebastian Arroyave (JS)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Yuval Elkun (Y)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Daniel Ranti (D)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

John L Pfail (JL)

Department of Urology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Rebecca Klahr (R)

Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA.

Olamide O Omidele (OO)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Victoria Adams-Sommer (V)

Department of Pharmacy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Gopi Patel (G)

Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Sarah Hall Schaefer (SH)

Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Conner Brown (C)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Ketan Badani (K)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Etienne Lavallee (E)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Reza Mehrazin (R)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Kyrollis Attalla (K)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Nikhil Waingankar (N)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Peter Wiklund (P)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

John P Sfakianos (JP)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: john.sfakianos@mountsinai.org.

Classifications MeSH